Daiichi/Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
This article was originally published in PharmAsia News
Executive Summary
The frequency of cancer tumors seen in the prasugrel arm of Lilly/Daiichi Sankyo's TRITON trial was not enough to seriously concern a U.S. FDA advisory committee as the panel voted unanimously to recommend approval of the platelet inhibitor
You may also be interested in...
Daiichi Sankyo Seeking Small Biotech Acquisitions In Europe
Daiichi Sankyo is scanning Europe for potential acquisitions that would help the Japanese company expand its market reach and enhance its product pipeline. Daiichi will focus on smaller biotechnology companies that have a strong oncology focus and a promising pipeline
Daiichi Sankyo Seeking Small Biotech Acquisitions In Europe
Daiichi Sankyo is scanning Europe for potential acquisitions that would help the Japanese company expand its market reach and enhance its product pipeline. Daiichi will focus on smaller biotechnology companies that have a strong oncology focus and a promising pipeline
Sun Pharma Managing Director Dilip Shanghvi On Building Its U.S. Base: An Interview With PharmAsia News (Part 2 of 2)
With a robust business strategy of strengthening its U.S. operations, India's Sun Pharmaceutical has emerged as the most valued Indian drug company. As stock markets hammered down valuations for other top Indian drug companies like Ranbaxy, Dr. Reddy's and Cipla, analysts have largely held Sun's valuations steady. In a rare interview with PharmAsia News' Indian bureau, Sun Pharmaceutical Chairman and Managing Director Dilip Shanghvi shares his thoughts on the long term goals for the company and speaks out on the tangle that his company is engaged in to acquire Israeli drug maker Taro.